Home Sectors Healthcare Current Performance: Incyte Corporation (NASDAQ: INCY)

Current Performance: Incyte Corporation (NASDAQ: INCY)

SHARE

Incyte Corporation trades as part of the healthcare sector and trades as part of the biotechnology industry. The company CEO is Herve Hoppenot. Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary therapeutics. Its product JAKAFI, a JAK1 and JAK2 inhibitor is used for treatment of patients with intermediate or high risk myelofibrosis.

Previous Intraday Trading Performance:

The INCY stock showed a previous change of 1.55% with an open at 80.79 and a close of 81.75. It reached an intraday high of 82.31 and a low of 80.26.

Business Wire:  FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Acute Graft-Versus-Host Disease

Liquidity:

The stock has a market cap of $17.5b with 214.4m shares outstanding, of which the float is 211.8m shares. Trading volume reached 1,450,121 shares compared to its average volume of 1,409,251 shares. Based on the current average volume and close price, the trading liquidity is good.

Historical Trading Performance:

Over the last five trading days, Incyte Corporation shares returned 6.40% and in the past 30 trading days it returned 2.96%. Over three months, it changed -5.90%. In one year it has changed 22.62% and within that year its 52-week high was 88.83 and its 52-week low was 57.00. INCY stock is 43.42% above its 52 Week Low.

Our calculations show a 200 day moving average of 73.49 and a 50 day moving average of 80.88. Currently INCY stock is trading 11.24% above its 200 day moving average.

SeekingAlpha:  FDA OKs Incyte’s Jakafi for GvHD

Earnings:

The last annual fiscal EPS for the company was reported at 0.51 that ended on 31st of December 2018, which according to the previous close, that is a PE of 160.29. Based on 1 analyst estimate, the estimated EPS for the next quarter is 0.23. The TTM EPS is 0.50, which comes to a TTM PE of 163.50.

Below was the last reported quarterly diluted earnings per share:

1stQtr of 2019 0.47
4thQtr of 2018 0.32
3rdQtr of 2018 0.14
2ndQtr of 2018 0.24
1stQtr of 2018 -0.19

Base on our calculations, the intrinsic value per share is 92.57, which means it is possibly undervalued and has a margin of safety of 11.69%.

Indicators to Watch:

The current calculated beta is 1.21.

SeekingAlpha:  FDA OKs Incyte’s Jakafi for GvHD

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 13.62%, return on assets is 10.00%, profit margin is 12.66%, price-to-sales is 8.64 and price-to-book is 8.41.

Company Scores:

All scores are out of six:
 0  :Valuation Score
 2  :Past Performance Score
 6  :Financial Strength Score
 4  :Future Growth Score
 0  :Dividend Score
 3  :Overall Score

SHARE
John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.